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Abstract
During the evolution into castration or therapy resistance, prostate cancer cells reprogram the androgen responses to cope
with the diminishing level of androgens, and undergo metabolic adaption to the nutritionally deprived and hypoxia
conditions. AR (androgen receptor) and PKM2 (pyruvate kinase M2) have key roles in these processes. We report in this
study, KDM8/JMJD5, a histone lysine demethylase/dioxygnase, exhibits a novel property as a dual coactivator of AR and
PKM2 and as such, it is a potent inducer of castration and therapy resistance. Previously, we showed that KDM8 is involved
in the regulation of cell cycle and tumor metabolism in breast cancer cells. Its role in prostate cancer has not been explored.
Here, we show that KDM8’s oncogenic properties in prostate cancer come from its direct interaction (1) with AR to affect
androgen response and (2) with PKM2 to regulate tumor metabolism. The interaction with AR leads to the elevated
expression of androgen response genes in androgen-deprived conditions. They include ANCCA/ATAD2 and EZH2, which
are directly targeted by KDM8 and involved in sustaining the survival of the cells under hormone-deprived conditions.
Notably, in enzalutamide-resistant cells, the expressions of both KDM8 and EZH2 are further elevated, so are
neuroendocrine markers. Consequently, EZH2 inhibitors or KDM8 knockdown both resensitize the cells toward
enzalutamide. In the cytosol, KDM8 associates with PKM2, the gatekeeper of pyruvate flux and translocates PKM2 into the
nucleus, where the KDM8/PKM2 complex serves as a coactivator of HIF-1α to upregulate glycolytic genes. Using shRNA
knockdown, we validate KDM8’s functions as a regulator for both androgen-responsive and metabolic genes. KDM8 thus
presents itself as an ideal therapeutic target for metabolic adaptation and castration-resistance of prostate cancer cells.
Introduction
One of the most troubling aspects of prostate cancer (PCa)
progression is the conversion from androgen-dependent to
independent (or castration-resistant) state, which at present
defies any effective treatment. The next-generation anti-
androgens, enzalutamide, and abiraterone have improved
the prospects, but eventually therapy-resistant PCa still
developed. During the evolution into castration or therapy
resistance, the tumor cells need to reprogram the androgen
responses to cope with the diminishing level of androgens,
and to undergo metabolic adaption to the nutritional and
hypoxia conditions during therapy. Increased aerobic gly-
colysis has been shown to be associated with castration or
therapy resistance [1–3]. Nearly all glycolytic genes are
overexpressed in advanced PCa [4], many of which are
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targets of HIF-1α [5]. One of the key factors regulating
glycolysis in tumor cells is PKM2, a cytosolic enzyme
which controls the level of pyruvate and its flow to lactate
versus mitochondria. Through ligand stimulation and post-
translational modifications, PKM2 can be translocated into
nucleus to become a coactivator for HIF-1α, thereby further
fueling the glycolytic pathway [6, 7]. Not surprisingly,
overexpression and modifications of PKM2 are associated
with PCa progression [8]. In the present study, we describe
a novel lysine demethylase which interacts with both AR
and PKM2 to reprogram androgen responses and tumor
metabolism.
Lysine demethylases (KDMs) have emerged as an
important class of epigenetic factors involved in carcino-
genesis. Among the eight KDM subfamilies, nearly all (e.g.,
KDM1, KDM2A-C. KDM3A, C, KDM4A-D, KDM5A-C,
KDM6B, C, KDM8 (this study)) have been found to be
overexpessed in PCa, and several of them correlate with
poor prognosis, indicating a critical role of histone deme-
thylation in tumorigenesis [9]. The most well-characterized
are the KDM1 and KDM4 subfamilies. It was found that
KDM1, KDM4A, B and C all associate with AR and serve
as coactivators [10, 11], and their overexpressions predict
poor prognosis of PCa [12, 13]. We recently reported that
genetic and pharmacological inhibitors to KDM4A and 4B
suppress the growth of PCa cells without affecting normal
prostate epithelial cells [14]. Duan et al. [15] reported a
similar finding with another KDM4A inhibitor. These data
suggest that KDMs are potential targets for PCa therapy.
KDM8/JMJD5, the newest member of the histone
demethylase family, is involved in embryogenesis [16],
oncogenesis [16, 17], and stem-cell renewal [18]. Over-
expression of KDM8 was observed in a variety of tumor
tissues [17, 19, 20] and knockdown of KDM8 compromised
the growth of cancer cells [16, 17] (and this study). Toge-
ther, they suggest a critical role of KDM8 in development
and cell growth. We and others [16, 17, 21–24] showed that
KDM8 is associated with H3K36me2 demethylation
in vivo. Macron et. al. identified RCCD1, a centromere and
DNA-binding protein, can augment KDM8’s activity [23,
25].Other studies suggest that KDM8 may also function as a
dioxygenase [26], and as an aminopeptidase, digesting
methylated histone tails to modulate chromatin conforma-
tion [27, 28]. Accumulating evidence suggest that KDM8 is
a key cell cycle regulator by upregulating Cyclin A [17, 22],
modulation of the expressions of p53 and p21 [16, 18, 22,
29, 30] and interactions with spindle microtubules [31]. In
addition, it is involved in regulating the fidelity of centro-
some duplication by suppression the expression of Satellite
repeats [23] and DNA recombination [24]. KDM8 shuttles
between cytosol and nucleus with the NLS recently mapped
at the N terminus with binding to importin [32]. Interest-
ingly, we reported that KDM8 facilitates the nuclear
translocation of PKM2 (pyruvate kinase M2 isoform), a
critical enzyme involved in tumor metabolism [7]. We
found that KDM8 binds PKM2 and enhances the conver-
sion of cytosolic tetramer form of PKM2 into the dimer or
heterodimer form which enters nucleus. Together with
KDM8, PKM2 serves as a coactivator of HIF-1α, to upre-
gulate enzymes involved in Warburg effect [7]. All data,
taken together, suggest KMD8 is a multi-functional mole-
cule involved in tumor progression, In this study, we extend
its oncogenic role to PCa.
Results
KDM8 is overexpressed in a subset of prostate
tumors with high Gleason scores and its elevation
drives the development of CRPC
We first examined whether KDM8 expression is deregu-
lated in tumors of PCa by immunohistochemistry (IHC)
analysis. Evaluation of anti-KDM8 immunostaining of
prostate specimens from 121 cases revealed that 61% of
malignant tumors showed high levels of KDM8 expression
while the majority of normal or non-malignant prostate
tissues displayed no detectable or low levels of KDM8 (Fig.
1a, b, Table S1). Approximately 80% of tumors with high
Gleason score (7–10) had positive KDM8 staining with
high IHC scores, while about 25% of low (2–6) Gleason
tumors displayed high KDM-IHC scores (Fig. 1b).
Similar to the expression pattern seen in prostate tissues,
higher levels of KDM8 protein were detected by immuno-
blotting in PCa cell lines as compared to immortalized
prostate epithelial cell line RWPE1 (Fig. 1c). In agreement
with our own screening results, the TCGA transcriptome
dataset extracted from Oncomine database (www.
oncomine.com) also showed a higher expression of
KDM8 in malignant PCa (p < 0.0001) (Fig. 1d). These data
suggest KDM8 may be involved in the development of
castration and therapy resistance.
Consistent with its role in the control of PCa cell pro-
liferation and survival, knockdown of KDM8 inhibited the
proliferation of both LNCaP, C4-2B and C4-2B-MDVR, an
enzalutamide-resistant variant of C4-2B, and, to less extent,
the AR negative PC3 cells. Importantly, KDM8 knockdown
had little effect on the non-malignant prostate cell line
RWPE1 (Fig. 2a and Figure S2). By contrast, over-
expression of KDM8 in RWPE1 cells stimulates the growth
of this cell line (Figure S1). These data suggest that KDM8
is related to malignant cell growth. We then asked whether
overexpression of KDM8 can convert an androgen-sensitive
LNCaP into androgen-independent. Accordingly, KDM8
was overexpressed in LNCaP cells via lentivirus infection
and cultured in androgen-deprived conditions. As shown in
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Fig. 2b and Figure S3a, KDM8 overexpression markedly
stimulated androgen-independent cell proliferation of
LNCaP cells.
These studies were then extended to in vivo tumorigen-
esis assay. KDM8 overexpressing and vector control
LNCaP cells (Figure S3b) were injected into athymic nu/nu
mice and the tumor growth was monitored. In intact ani-
mals, the KDM8-overexpressing LNCaP grew slightly
faster than vector- infected LNCaP (LNCaP-LKO). Upon
castration, LNCaP-KDM8 tumors continued to grow
whereas LNCaP-LKO ceased to do so (Fig. 2c). Together,
these data suggest that elevated KDM8 expression is related
to malignant transformation of PCa cells and has the
potential to cause castration-resistance.
KDM8 regulates tumor metabolism via partnership
with PKM2
KDM8 translocates PKM2 into nucleus
One of the hallmarks of aggressive PCas including castra-
tion and therapy resistant is the metabolic adaptation, where
aerobic glycolysis dominant over mitochondria oxidative
phosphorylation [1, 2]. Previously, we reported that in
breast cancer, a novel function of KDM8 is its association
with PKM2 and its ability to translocate PKM2 into nucleus
to become a coactivator of HIF-1α to transcriptionally
activate glycolytic genes in favor of Warburg effects [7].
We therefore asked whether KDM8 is able to modulate the
tumor metabolism in PCa cells. First, in a reciprocal
immunoprecipitation analysis, we showed that KDM8 and
PKM2 associate with each other in LNCaP cells (Fig. 3a).
Furthermore, in both cell fractionation and confocal
microscopy analyses, KDM8 overexpression enhances the
translocation of PKM2 into the nucleus (Fig. 3b, c). Con-
versely, knockdown of KDM8 reduces PKM2 translocation
(Fig. 3b, c). The nuclear translocation studies were aided by
confocal microscopy (Fig. 3c) where the fluorescent inten-
sity of PKM2 across the nucleus was traced as illustrated on
the right panel and the average intensity of counting 10
nuclei for KDM8 overexpressing cells measured.
KDM8/PKM2 upregulates glycolytic genes
A consequence of the KDM8-mediated PKM2 nuclear
translocation is the upregulation of glycolytic and metabolic
genes, the targets of HIF-1α [7]. The genes involved in
glycolysis upon KDM8 overexpression shown in Fig. 4a
Fig. 1 KDM8 is overexpressed in malignant prostate tissues and
cancer cell lines. a Representative images of anti-KDM8 immuno-
histochemical (IHC) staining of prostate normal and malignant tissue
sections. b Percentage of prostate cancer tumors with different Gleason
scores that are scored as high or low (or negative) in the anti-KDM
IHC analysis. c Western blot analysis of KDM8 in non-malignant
RWPE1 cell line and cancerous prostate epithelial cell lines C4-2B,
LNCaP, PC3, CWR22rv1, and DU145. GAPDH was used as a loading
control. d KDM8 gene expression analysis in prostate cancer (TCGA
dataset extracted from Oncomine database). Box plot derived from
gene expression data in Oncomine database comparing the KDM8
expression in normal (n= 184) and in malignant cancer tissues (n=
141)
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(GLUT1, HK2, PKM2, LDHA, etc.) are all upregulated,
whereas genes involved in mitochondrial pyruvate flow
such as PDHA1 and PDHB1 are down-modulated. These
data are summarized in the bubble diagram of Fig. 4d. The
overall consequence is the switch of mitochondria oxidative
phosphorylation to glycolysis [7]. Indeed, in LNCaP-
KDM8 cells, the uptake of glucose (Fig. 4b) and lactate
production (Fig. 4c) are increased over the control cell lines,
and they are PKM2-dependent, as siRNA targeting PKM2
reverse the effects. To demonstrate that the heightened
expression of glycolytic genes by KDM8 overexpression is
mediated by PKM2, we knocked down PKM2 in LNCaP-
KDM8, and monitored their expression levels (Fig. 4a, right
panel and Figure S4). Many of the genes overexpressed in
LNCaP-KDM8 are indeed down-modulated in the absence
PKM2. Taken together, these data suggest that KDM8 is a
major metabolic regulator, in partnership with PKM2, forms
a complex that translocates into the nucleus to reprogram
gene expression toward aerobic glycolysis (Warburg effect)
(Fig. 4d).
KDM8 regulates androgen responses via partnership
with AR
KDM8 activates AR response in the absence of androgen
In addition to metabolic adaptation, aberrant activation of
AR responses is another critical step of castration-
resistance. In our transcriptome analysis of KDM8 over-
expressing cells (microarray data were deposited in NCBI
Fig. 2 KDM8 is required for AR-positive prostate cancer cell pro-
liferation and survival, and promotes androgen-independent cell pro-
liferation and tumor growth. a Growth curves of non-malignant cell
line RWPE1 and prostate cancer cell lines LNCaP, PC3, C4-2B, and
C4-2B-MDVR, an enzalutamide-resistant cell line. Cells were trans-
fected with small interfering (si)-RNAs targeting KDM8 or si-non-
targeting (NT) control. Every 2 days after transfection, cell prolifera-
tion was measured by MTT assay. b Growth curves of LNCaP cells
infected with KDM8 overexpressing (KDM8) or control (LKO) len-
tiviruses followed by maintaining in androgen-deprived media. Two
days later infection, cell proliferation was measured by MTT assay at
indicated times. c Tumor growth curves of KDM8 overexpressing and
LKO control LNCaP cells in xenografting mouse model. Cells were
injected subcutaneously into the dorsal flanks of athymic nude mice (8
mice per group) and tumor volumes were measured every week by
using calipers. Tumor-bearing mice were also castrated at indicated
time point. Insert: photograph of xenograft tumors. The quantitative
data shown in a and b are the mean ± S.D. of three separate experi-
ments. The average tumor volumes are presented as the mean ± S.E.M.
*p < 0.05; **p < 0.01, by paired Students’ t (MTT assay) or ANOVA
test (xenografting study)
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GEO database accession number: GSE56908), unsu-
pervised clustering analysis (Fig. 5a) indicated that among
the genes modulated by KDM8 (in the absence of DHT), a
significant fraction corresponds to androgen response genes,
which include AMACR, EZH2, ANCCA, KLK3, and
NSD2/WHSC1, suggesting KDM8 overexpression leads to
aberrant activation of AR. Real-time RT-PCR validated the
microarray results (Fig. 5b). As shown in the Venn diagram
(Fig. 5c), a significant fraction of genes (27% in the absence
of DHT and 37% in the presence of DHT) with altered
expression (2×) elicited by elevated KDM8 overlap with
androgen-responsive genes (ARG).
Genes involved in androgen-independent growth
To demonstrate that the KDM8-upregulated genes are
functionally relevant in the induction of androgen-
independence, we individually knocked down the upregu-
lated genes (Figure S6) and monitor the growth of LNCaP-
KDM8 in regular and in charcoal-dextran media (Fig. 5d).
In regular media, the individual knockdowns had moderate
effects (dark red to light red), while in charcoal-stripped
media, as expected, the LNCaP-EV cells were not growing
well, with individual knockdown of many of the genes
including EZH2 caused severe effects. In LNCaP-KDM8,
the effects of individual gene knockdown of on growth are
generally minimal. In charcoal-stripped media, the inhibi-
tory effects on growth of individual knockdown of genes
such as EZH2 were again detected. These results suggest
that KDM8 induced genes (in the absence of androgen)
were indeed relevant to androgen-independent growth, and
they jointly contribute to the growth and survival of LNCaP
under androgen-deprived conditions.
Fig. 3 KDM8 regulates PKM2 nuclear translocation. a Interaction of
endogenous KDM8 and PKM2 in LNCaP cells. Reciprocal immuno-
precipitation (IP) and immunoblotting (IB) were performed with
PKM2 and KDM8 antibodies as indicated. b Subcellular localization
of KDM8 and PKM2 in LNCaP cells. Nuclear (Nuc) and cytosolic
(Cyto) fractions were prepared from LNCaP cells transfected with si-
NT, si-KDM8, EV, or KDM8-expressing vector, followed by immu-
noblotting analysis with antibodies as indicated. KDM8*, Flag-tagged
KDM8. c Confocal immunomicroscopy analysis of PKM2 nuclear
translocation. Treated cells were fixed and immunostained with anti-
PKM2 (PKM2) and 4′,6-diamidino-2-phenylindole (DAPI, nucleus),
respectively. The framed regions marked in the merged images
(Merge) are zoomed at the next (Zoom). The line profiles of PKM2
and DAPI signals were measured by ZEN 2011 (Carl Zeiss, Germany)
software. Scale bars, 10 µm
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KDM8 associates with AR and acts as a novel AR
coactivator
KDM8 associates with and transactivates AR
Given that a majority of ARGs were regulated by KDM8,
we asked whether KDM8 physically associates with AR
and serves as a coactivator [33, 34]. We first performed co-
immunoprecipitation assay. As shown in Fig. 6a, anti-AR
antibody, but not the control IgG, effectively co-precipitated
KDM8, demonstrating that indeed KDM8 specifically
formed complexes with AR. To further characterize the
interaction, we expressed Flag-tagged KDM8, together with
Myc-tagged AR full-length (FL) or its deletion mutants: N
(N-terminal domain, NTD), ND (NTD plus DNA-binding
domain, DBD), or DL (DBD plus ligand-binding domain
LBD) in 293T cells and performed immunoprecipitation
with Flag-tagged KDM8, and detected strong association of
KDM8 with DBD-LBD but not with the NTD (Fig. 6b).
The mapping data suggest that the interaction domain of AR
resides in the ligand-binding domain.
To determine whether KDM8’s interaction with AR
affects the transcriptional regulation activity of AR, we
performed reporter gene assays with PSA gene enhancer
and promoter-linked luciferase. Figure 6c showed that
although KDM8 alone slightly induced the reporter activity,
co-expression of KDM8 and AR markedly increased the
reporter activity from 4-fold (AR alone) to 15-fold (AR+
KDM8) and from 15-fold (AR alone) to 38-fold (AR+
KDM8) in the absence and presence of DHT, respectively.
Interestingly, changes in the amino acid sequence in the
Jumonji domain (H321A), which inactivates its demethy-
lase activity, only partially reduced the coactivation of AR,
indicating the KDM8 behaves in both demethylase depen-
dent and independent manner.
Fig. 4 Overexpression of KDM8 reprograms glucose metabolism in
prostate cancer cells. a Heat map of metabolic gene expression in
KDM8-overexpressed LNCaP cells (left panel) and the KDM8-
overexpressed LNCaP cells knocking down with siRNA targeting
PKM2 (right panel). The gene expression levels were measured by
qRT-PCR. Data were analyzed as fold change as compared to the EV
control (left panel) or si-NT after normalizing to internal control, 16S
rRNA. b Measurements of the levels of extracellular lactate and c
glucose update in EV control and KDM8-overexpressed LNCaP cells.
Data are expressed as mean ± S.D. with three separate experiments. *p
< 0.05. d A schematic diagram of glucose metabolic flux. Over-
expression of KDM8 induces redirection of metabolic flux into the
biomass synthesis pathways. The affected genes are marked in red
(upregulated) or in blue (downregulated). The sizes of the circles are
proportional to the expression levels of the genes indicated
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KDM8 is corecruited with AR to PSA promoter and
enhancer
To study whether KDM8 functions as an AR coactivator
in vivo, we studied the co-recruitment of KDM8 and AR at
the enhancer and promoter regions of PSA by ChIP assays
(Fig. 6d). In parental LNCaP, KDM8 was seen to occupy
both the enhancer and promoter region of PSA locus under
androgen-deprived conditions. In KDM8 overexpressing
LNCaP, increased occupancy of KDM8 was detected. The
level of AR also increased under these conditions, sug-
gesting that KDM8 facilitates the recruitment of AR to the
target sites. Together, these results demonstrate that KDM8
can act as a novel AR coactivator through its direct inter-
action with AR.
KDM8 mediates AR activation of EZH2 via ANCCA to
stimulate PCa cell growth
To further validate KDM8 as a critical coactivator of AR in
prostate carcinogenesis, we wish to identify the recruitment
of KDM8 to the promoters of AR target genes involved in
tumor progression. We have selected EZH2 pathway to
illustrate the role of KDM8. EZH2 is among the genes
whose knockdown have the most severe effects on
androgen-independent growth and that there is strong evi-
dence that EZH2 is involved in PCa progression (see Dis-
cussion). We previously showed that EZH2 is activated by
AR via ANCCA, a chromatin remodeling ATPase and a
coactivator of E2F1 [35], which is also upregulated by
KDM8 overexpression (Fig. 7a) (Supplementary Informa-
tion Figure S1b). Here, we show that KDM8 is directly
Fig. 5 KDM8 controls specific subsets of androgen-responsive pro-
gram. a Heat map of hierarchical clustering of androgen-regulated
genes (ARGs). LNCaP-overexpressed KDM8 and EV control cells
were cultured in the presence or absence of 1 nM DHT followed by
gene expression profiling with microarray analysis. The ARGs that
differentially expressed by KDM8 (≥1.5-fold) and the positions for
well-known ARGs are indicated. Two genes EZH2 and ANCCA
selected for ChIP assay are marked in red. b qRT-PCR analysis of the
selected ARDs. LNCaP cells (KDM8 and EV) were cultured in the
androgen-deprived media for 3 days followed by qRT-PCR analysis.
Triplicate experimental data were expressed as fold change as com-
pared to EV control after normalizing to internal control 16S rRNA. c
Venn diagram showing the overlap of KDM8-regulated genes and
ARDs. d Heat map showing cell viability of LNCaP cells (KDM8 and
EV) by knocking down the indicated ARGs in the absence of andro-
gen. LNCaP cells infected with the shRNAs targeting the ARGs as
indicated were then cultured in media containing normal FBS or
charcoal-stripped FBS (CS-FBS) for 3 days. Cell viability was
assessed by MTT assay. EZH2 and ANCCA selected for chromatin
immunoprecipitation (ChIP) assay are marked in red
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involved in both ANCCA and EZH2 activation in LNCaP
cells. We first demonstrated that KDM8 was corecruited
with AR to the enhancer region of ANCCA locus in both
the control (EV) and KDM8 overexpressor (KDM8) (Fig.
7b, upper panel). The amount of AR recruitment increases
with KDM8 overexpression, suggesting that KDM8 as a
coactivator facilitates AR targeting to chromatin. Further-
more, the co-recruitment of KDM8 and AR were induced
by androgen in a time-dependent manner (Fig. 7b, lower
panel), followed by the recruitment of RNA polymerase II
(Pol II) for transcription. The elevated expression of
ANCCA lead to an increased accumulation of ANCCA and
its transcriptional partner E2F1 near the promoter of EZH2
[35], as seen in KDM8 overexpressing cells (Fig. 7c, upper
panel). Importantly, we found KDM8 is also recruited to
this site in a time-dependent manner (Fig. 7c, lower panel).
Fig. 6 KDM8 acts as a novel coactivator of AR. a Interaction of
endogenous KDM8 and AR in LNCaP cells. Reciprocal immunopre-
cipitation (IP) and immunoblotting (IB) were performed with PKM2
and AR antibodies as indicated. Input indicates non-
immunoprecipitated cell lysates. b Schematic diagram of different
MYC-AR expression vectors. NTD N-terminal domain, DBD DNA-
binding domain, LBD ligand-binding domain, MYC-AR-FL (full
length), MYC-AR-ND, NTD+DBD; MYC-AR-N, NTD; MYC-AR-
DL, DBD+ LBD. c Co-IP and IB of FLAG-KDM8 with different
Myc-AR constructions with anti-M2-Flag and Myc antibodies as
indicated. Non-immunoprecipitated samples are indicated as lysate. d
PSA promoter activity in prostate cancer cell line PC3. Dual luciferase
assays were performed in PC-3 cells transfected with PSA-luc/TK-
rellina (20:1) combining with the expression vectors of AR and KDM8
(wild-type and mutant H321A) as indicated. At 24 h after transfection,
the cells were cultured in RPMI-1640 medium with CS-FBS for 6 h
prior to treatment with 10 nM DHT for 8 h before measurement of the
luciferase activity. The relative luciferase activity (RLU, relative light
unit) was calculated by their normalized luciferase activity to the EV
control with (red bar) or without DHT (blue bar) stimulation. Error
bars represent as mean ± S.D. from three different experiments. #, *p <
0.05, ##, **p < 0.01, by paired Students’ t-test. e ChIP assay of KDM8
and AR binding to the PSA enhancer/promoter regions in LNCaP
cells. (Upper) Schematic diagram of the positions of PSA enhancer
and promoter. The distances of the enhancer and promoter from
transcription starting site (+1) as well as AR and KDM8 are presented.
Primer sets used for qPCR are indicated. (Lower) ChIP-qPCR analysis
of the occupancy of AR and KDM8 at PSA promoter and enhancer
regions. LNCaP cells maintained in androgen-deprived media were
used for the preparation of immunoprecipitated genomic DNA with
AR or KDM8 antibody as indicated. Data were expressed relative to
relevant IgG control. Data are shown as mean ± S.D. of three inde-
pendent experiments. *p < 0.05, by paired Students’ t-test
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Finally, to validate the roles of ANCAA and EZH2 in
KDM8-mediated growth, these genes were knocked down
in LNCaP-KDM8 (Supplementary Information Figure S7a,
c), and cell growth was significantly diminished in a manner
similar to KDM8 knockdown (Supplementary Information
Figure S7b, d). Taken together, these results confirmed
KDM8’s role as a coactivator of AR and is involved in the
activation of EZH2.
Fig. 7 KDM8 facilitates AR and E2F1 recruitment to the ANCCA and
EZH2 promoters and upregulation of ANCCA and EZH2 gene
expressions. a Immunoblotting assay of EZH2 and ANCCA in the
KDM8-overexpressing LNCaP cells. Cells transfected with FLAG-
tagged wild-type KDM8 or mutant KDM8-H321A were analyzed by
immunoblotting (IB) with the indicated antibodies. GAPDH was used
as a loading control. b ChIP analysis of the association of KDM8, AR,
and E2F1 binding to ANCCA enhancer/promoter in LNCaP cells.
(Upper) Schematic diagram of the positions of ANCCA enhancer and
promoter. The transcription starting site is marked as +1. (Lower)
ChIP-qPCR analysis of the occupancy of AR/KDM8 and KDM8/E2F1
at ANCCA enhancer and promoter, respectively. The immunopreci-
pitated chromatins were prepared from LNCaP cells maintained in
androgen-deprived media followed by immunoprecipitation with
indicated antibodies. Data were expressed as percent immunoprecipi-
tation relative to input chromatin. Data are shown as mean ± S.D. of
triplicate experiments. *p < 0.05, Student’s t-test. c ChIP analysis of
the association of KDM8, E2F1, and ANCCA binding to EZH2 pro-
moter in LNCaP cells. (Upper) Schematic diagram of the position of
EZH2 promoter. The transcription starting site is marked as +1.
(Lower) ChIP-qPCR analysis of the occupancy of KDM8/E2F1/
ANCCA at EZH2. The immunoprecipitated chromatin was prepared
from LNCaP cells maintained in androgen-deprived media followed
by immunoprecipitation with the indicated antibodies. Pol II, RNA
polymerase II. Data were expressed as percent immunoprecipitation
relative to input chromatin. Data are shown as mean ± S.D. of triplicate
experiments. *p < 0.05, Student’s t-test
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Targeting KDM8 in therapy-resistant PCa cells
There have been significant interests in developing therapies
overcoming castration as well as enzalutamide resistance.
We have developed an enzalutamide-resistant C4-2B cell
line, C4-2B MDVR [36]. As shown in Fig. 8a, C4-2B
MDVR has a heightened expression of KDM8, accom-
panied by elevated expression of EZH2, as compared to the
enzalutamide-sensitive C4-2B. TCGA public data analysis
revealed a general positive correlation of KDM8 and EZH2
in PCa cells (Fig. 8b). Both the in vitro (Fig. 2a) and in vivo
(Figure S8) growth of C4-2B-MDVR is inhibited by KDM8
Fig. 8 Overexpression of KDM8 confers upregulation of neuroendo-
crine markers and renders prostate cancer cells more sensitive to
killing by EZH2 inhibitors. a Immunobloting assay of KDM8
expression in C4-2B cell line and its enzalutamide-resistant derivative,
C4-2B-MDVR. α-tubulin and GAPDH were used as a loading control.
b Correlation analysis between gene expression levels of KDM8 and
EZH2 in prostate cancer patients (right panel) and normal controls (left
panel) from TCGA dataset extracted from Oncomine database. Pear-
son’s correlation (r) values are shown in each graph. c Cell survival
curves of C4-2B and C4-2B-MDVR cells treated with EZH2 inhibi-
tors. Cells were exposed to the EZH2 inhibitors GSK343 and GSK126
in different doses from 0 to 50 μg/ml for 72 h followed by MTT assay.
Data were expressed as the mean ± S.D. of triplicate experiments. The
values of IC50 were calculated and shown. The regression lines
represent the fit to a non-linear regression model using GraphPad
Prism. d qRT-PCR analysis of KDM8, EZH2, AR, and neuroendo-
crine markers mRNA expression. Parental cell lines (C4-2B) and the
enzalutamide-resistant derivative (C4-2B-MDVR) were transfected
with si-RNAs targeting KDM8 (si-KDM8) or non-targeting control
(si-NT) for 48 h. The relative mRNA levels of the above genes were
normalized to 18S rRNA. Data were represented as the mean ± S.D. of
triplicate experiments. Values in C4-2B cells transfected with si-NT
were set to 1. *,#p < 0.05, **, ##p < 0.01, by paired Students’ t-test. e
Model of KDM8-driven CRPC and neuroendocrine markers expres-
sion via AR–EZH2 axis
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knockdown. We show here that C4-2B-MDVR is sensitive
to cell killing by two EZH2 inhibitors (GSK343 and
GSK126) (Fig. 8c). Interestingly, C4-2B-MDVR is more
sensitive to EZH2 inhibitor than its C4-2B, despite the
higher EZH2 expression level. This suggests that during the
selection of enzalutamide resistance, C4-2B-MDVR has
developed a reliance on the EZH2 pathway. One potential
mechanism is the adaptation of neuroendocrine phenotypes,
caused by EZH2 overexpression [37]. Indeed, in C4-2B-
MDVR cell line, the expressions of neuroendocrine marker
genes (NSE, SYP, and HTRSA) are elevated over C4-2B
(Fig. 8d). Moreover, siRNA knockdown of
KDM8 significantly decreased the expression of neu-
roendocrine genes, suggesting that the KDM8–AR–EZH2
axis may be involved in the generation of neuroendocrine
phenotypes (Fig. 8e), thereby conferring resistance to
enzalutamide. EZH2 inhibitor or KDM8 knockdown
reverses this trend and resensitizes these cells toward
enzalutamide.
Discussion
Androgen ablation therapies, especially with the next-
generation anti-androgen ezalutamide and androgen synth-
esis blocker abiraterone, are effective when cells are
dependent on androgen for their growth. Additional thera-
pies and molecular targets are being sought to help targeting
PCa cells which either harbor aberrantly activated,
androgen-independent AR or constitutively activated
oncogenes bypassing the need of AR signaling. In this
study, we show that KDM8 could be such a target as it is
involved in aberrant AR as well as AR-independent sig-
naling by being a partner for both androgen receptor and
PKM2. Androgen receptor and PKM2 are both engines for
PCa growth, as the former regulates cell cycle, and the
latter, tumor metabolism. Adaptation to tumor metabolism
is also important for tumor cells to escape the nutrition
deprived conditions during therapeutic intervention. Indeed,
Gene set enrichment analysis (GSEA) in KDM8-high
prostate clinical samples several metabolic pathways
including those involved in lipid, glycolysis, and pyruvate
are enriched (Figure S9). Thus, targeting KDM8 should not
only thwart castration-resistance but may also reduce ther-
apy resistance.
KDM8 as a coactivator of PKM2
PKM2 is a pivotal enzyme in determining the metabolic
flow to lactate, TCA cycle, or biosynthetic pathway [38].
For tumor cells, PKM2 enzymatic activity is required, but
should be maintained at a balanced level, high enough to
produce sufficient pyruvate, but low enough to accumulate
enough glycolytic precursors for the biosynthesis of mac-
romolecules. PKM’s activity can be modulated by a variety
of ways including metabolite binding [39, 40] and post-
translational modifications [41–44]. An additional way is to
divert some of the cytosolic PKM2 into nucleus where it
serves as a coactivator to transcriptionally activate more
metabolic genes [6, 45, 46]. The mechanisms associated
with PKM2 translocation are multiple, including phos-
phorylation, [47] acetylation [43], and hydroxylation [45].
Here, we describe another way whereby KDM8 binds
PKM2 and transports PKM2 into the nucleus and enhances
metabolic gene expressions. Nearly all the glycolytic
enzymes have higher level of expressions to accelerate the
glycolysis reactions. Many of these genes are targets of
HIF-1a. Their upregulations depend on the presence of both
KDM8 and PKM2, as knockdown of either one diminished
the effects.
KDM8 as a coactivator of AR
KDM8 is overexpressed in nearly all PCa cell lines and in a
significant portion of high-grade PCas. Its overexpression
leads to AR activation under androgen-deprived conditions
and confers castration-resistance in xenograft model.
Knockdown of KDM8 preferentially affected the growth of
PCa cells with virtually no effects on normal prostate epi-
thelial cell. We showed that KDM8 is a bona fide AR
coactivator by demonstrating its association with AR,
synergistic activation of ARE-driven promoters with AR,
and co-recruitment with AR to the target sites. The exten-
sive overlap of KDM8 and AR-activated genes lends cre-
dence to the notion that KDM8 is a natural coactivator of
AR. At present, we do not know how KDM8 enhances AR
activity. Our data suggest that it facilitate the delivery of AR
to the chromatin targets, likely due to KDM8’s ability to
modulate the chromatin conformation. In this regard, we
found that the demethylase activity for H3K36me3, how-
ever, is not absolutely required for co-activating AR. It is
possible the newly discovered cleavage activity may mod-
ulate the chromatin structure without demethylase activity
[27, 28].
KDM8/AR signaling network
Overexpression of KDM8 leads to castration-resistance as
determined by in vitro culture and in vivo xenograft model
and the upregulation of a subset of AR responsive genes.
Many of these genes have been reported to be important
factors in castration-resistance. We wished to determine
which of them are important downstream effectors of
KDM8-mediated castration-resistance. Based on an
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unbiased siRNA screening, we found that all individually
contributed to some extent to the growth and survival
phenotypes under androgen-deprived conditions, with the
knockdown of EZH2, AMACR, NSD2, MCM3, ETV1, and
CD24 giving the most severe consequence. We chose EZH2
to further define the detailed mechanisms of upregulation,
because of its well-recognized role in castration-resistance
[48, 49], EMT/metastasis [50, 51], chemoresistance [52],
and neuroendocrine phenotypes [53] of PCa. EZH2, the
catalytic subunit of the polycomb repressive complex
PRC2, is a general repressor of gene transcription and
shown to be a corepressor of androgen receptor in PCa [54].
Interestingly, in castration-resistant PCa, EZH2 also acts as
a coactivator to modulate genes involved in castration-
resistance [55]. EZH2 is commonly overexpressed in PCas
[48] with the highest expression in lethal-type castration-
resistance PCa [56]. Our studies provide additional insights
into the regulation of the EZH2 in PCa. Our data suggest
that KDM8 and ANNCA are recruited to the promoter of
EZH2 and regulate its expression. Our data confirmed
previous results showing ANCCA is a direct target of AR
and further indicate that KDM8 also participates in the
transcription of this gene.
KDM8/EZH2 and enzalutamide resistance
The second-generation anti-androgen enzalutamide has
improved the prospects of castration-resistance patients.
However, enzalutamide-resistant tumors eventually emerge,
leading to mortality. Some of the resistant cells, especially
those with RB, p53, and PTEN defects, is marked by an
intermediate phenotype with the expression of both andro-
gen receptor and neuroendocrine markers [37]. EZH2 or
polycomb complex was shown to be an inducer of the
neuroendocrine phenotypes [53, 57]. Inhibition of EZH2
reverses the phenotypes and resensitize the resistant cells
toward enzalutamide [37]. As KDM8 is an upstream reg-
ulator of EZH2 as shown in this study, we checked whether
heightened KDM8 expression is associated with enzaluta-
mide resistance. In the enzalutamide-resistant C4-2B-
MDVR line we developed [1], KDM8 expression was ele-
vated, which is accompanied by upregulation of neu-
roendocrine genes. These clones are more sensitive to
EZH2 inhibitor and KDM8 knockdown reduces neu-
roendocrine markers, overcoming enzalutamide resistance.
These data suggest that KDM8 may have a role in therapy
resistance as well.
In summary, we have identified KDM8 as a dual coac-
tivator of AR and PKM2, which drives PCa growth and
provides needed metabolic energy. These properties, toge-
ther with its ability to activate EZH2, a factor known to be
involved in castration and therapy resistance, make KDM8
a promising therapeutic target for PCa.
Materials and methods
Cell lines and cell culture
RWPE1, LNCaP, PC3, C4-2B, DU145, CWR22V1, and
HEK293 cells were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). C4-2B cells
resistant to enzalutamide (C4-2B-MDVR) were generated
by culturing C4-2B cells to increasing concentrations of
enzalutamide (5–40 µM) in media for over 12 months and
maintained in complete media supplemented with 20 µM
enzalutamide as described previously [58, 59]. HEK293
cells were cultured in complete DMEM medium. RWPE1,
LNCaP, LNCaP-KDM8 [17], PC3, C4-2B, DU145, and
CWR22RV1 cells were cultured in RPMI-1640 medium
supplied with 10% heat-inactivated FBS, 100 U/ml peni-
cillin, and 0.1 mg/ml streptomycin in a humidified incubator
with 5% CO2. For hormone induction experiments, the
growth media were replaced by RPMI-1640 containing
10% charcoal-dextran-treated (CDT) FBS (CDT-FBS) for
2 days before treatment with 10 nM dihydrotestosterone
(DHT).
Cell proliferation and survival assays
Cells were seeded in 48-well plates in RPMI-1640 complete
medium one day before KDM8 knocking down experi-
ments. After incubation for 24 h, the cells were then trans-
fected with si-RNAs of non-targeting control (si-NT) or
specific targeting KDM8 (si-KDM8#1 and si-KDM8#2).
The cell proliferation was measured every 2 days by MTT
colorimetric assay according to the manufacturer’s instruc-
tion (Roche, IN). C4-2B and C4-2B-MDVR cells were
seeded on 96-well plates at a density of 1 × 104 cells per
well in RPMI-1640 media containing 10% FBS and treated
with different concentrations of EZH2 inhibitors (GSK343
and GSK126) for 48 h. Cell viability was determined by the
MTT colorimetric assay and the cell survival rate (%) was
calculated as cell survival rate (%)= (OD570 nm of treat-
ment group/OD570 nm of control group) × 100%.
PSA-luciferase activity assay
The PSA-luciferase activity assay in PC-3 cells was as
described previously [60].
Co-immunoprecipitation and immunoblotting
analysis
Co-immunoprecipitation was performed using cell lysates
from LNCaP and 293T cells for endogenous and ectopically
expressed proteins, respectively, for investigating
protein–protein interaction has been described [7]. The
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immunoblotting assay was performed using the following
antibodies: Flag-M2, Myc-tag (Cell Signaling), KDM8
[17]; β-actin (Sigma-Aldrich); PSA (Santa Cruz Biotech);
ANCCA [61], EZH2 (Cell signaling), and GAPDH (Santa
Cruz Biotech).
Chromatin immunoprecipitation assay
ChIP assay was performed as described previously [61, 62].
The precipitated chromatin DNA was analyzed by real-time
PCR with SYBR green on an iCycler instrument (BioRad)
with gene specific primer sets (Supplementary Information).
Microarray assay
LNCaP cells overexpressing KDM8, KDM8-H321A, or EV
were grown in 10 cm dishes, and total RNAs were extracted
from 80% confluent cell using TRIzol (Invitrogen) extraction
according to the manufacturer’s instructions. Microarray gene
expression profiling was performed by 3′ IVT expression
analysis with Affymetrix GeneChip Human Genome U133
Plus 2.0 Arrays. The KDM8-responsive and androgen-
responsive gene expression changes were identified by pair-
wise comparison analyses (≥1.5-fold threshold), and expres-
sion patterns were analyzed by hierarchical clustering.
Mouse xenograft tumor study
Xenograft tumor studies were conducted utilizing the 6-
week-old male athymic Nu/Nu mice (Harlan). The total
number of mice (16) was randomly divided into two sets of
8 each. Mice of the two sets were inoculated sub-
cutaneously with one million of LNCaP cells over-
expressing KDM8 or vector control (EV) in 100 μl of 50%
Matrigel (BD Biosciences), respectively. Tumor growth
was monitored and the length (L), width (W), and height
(H) measurements taken every 7 days. The tumor volume
was calculated using the formula (L ×W ×H) × 0.52. For
castration study, the tumor-bearing mice were castrated
when the tumors reached their, respectively, peak volumes
(6-week post injection). All mice were killed by 10 weeks
post injection. The animal tumor studies were approved by
National Health Research Institutes Institutional Animal
Care and Use Committee (approval number: NHRI-
IACUC-102087) and carried out under the institutional
guidelines with animal welfare standards.
IHC and statistics analysis
IHC was performed as described previously [62] with the
following modifications. Two tissue microarrays from US
Biomax were used, which were TMA PR751 containing 73
IHC-scorable cores from 73 cases and TMA PR952
containing cores from 48 cases, with normal prostate tissues
adjacent to tumors and Gleason scores. The slides were then
incubated with anti-KDM8 rabbit polyclonal antibody
(homemade) at 1:100 dilutions overnight at 4 °C, followed
by incubations with biotinylated secondary antibody and the
ABC reagents in the Vectastain Elite kit and counter-stained
with hematoxylin. The percentage of positive nuclear
staining was scored as follows: 0–<5%, scored as KDM8-
negative or non-detected; 5–<25%, scored as KDM-low;
and >25%, scored as KDM-high. Differences and correla-
tions in immunostaining among groups were analyzed with
χ2 or Fisher’s exact test.
Confocal microscopy analysis
Confocal microscopy analysis for assessment of PKM2
nuclear translocation was performed as described pre-
viously [7].
Glucose uptake assay and lactate production assay
Glucose uptake assay and lactate production assay were
described previously [7].
Nuclear and cytosolic fractionation
Fractionation of nuclear and cytosolic extracts was per-
formed by using NE-PER® Nuclear and Cytoplasmic
Extraction kit (Thermo Scientific) according to the manu-
facturer’s instruction. Overall, 15 µl of each fraction was
analyzed immunoblotting assay.
Oncomine data analysis
KDM8 and EZH2 expression in PCa patient cohorts was
extracted from Oncomine database (www.oncomine.com)
[63]. In the database, the Cancer Genome Atlas (TCGA)
dataset was extracted and used to compare the differences of
clinical specimens between cancer and normal by using a
threshold of p < 0.05. Statistical analysis was performed
with one-way ANOVA or two-tailed t-tests. Correlation
between EZH2 and KDM8 was assessed by using the
Pearson correlation coefficient.
Statistical analysis
Comparisons were performed with a Student’s t-test with p-
values denoted as *p < 0.05 and **p < 0.01 (N.S., not sig-
nificant). Graphpad Prism software (La Jolla, CA, USA)
was used to calculate mean and standard deviation.
Acknowledgements This work was supported by grants CA114575,
CA165263, and CA206222 from NIH, USA; NHRI03A1-
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC 29
MGPP18–014, NHRI04A1-MGPP15-014, and NHRI05A1-MGPP15-
014 from NHRI, Taiwan; MOHW104-TDUM-212-13304 from
MOHW of Taiwan; MOST102-2320-B-400-018-MY3 and
MOST104-2321-B-400-009 from MOST of Taiwan; The UCDCCC
Genomics Shared Resource is funded by the UC Davis Comprehensive
Cancer Center Support Grant (CCSG) awarded by the National Cancer
Institute (NCI P30CA093373). We thank Taiwan Bioinformatics
Institute Core Facility for assistances on using Oncomine (National
Core Facility Program for Biotechnology, MOST 105-2319-B-400-
001).
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflict of
interest.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as
long as you give appropriate credit to the original author(s) and the
source, provide a link to the Creative Commons license, and indicate if
changes were made. The images or other third party material in this
article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons license and your intended
use is not permitted by statutory regulation or exceeds the permitted
use, you will need to obtain permission directly from the copyright
holder. To view a copy of this license, visit http://creativecommons.
org/licenses/by/4.0/.
References
1. Cui Y, Nadiminty N, Liu C, Lou W, Schwartz CT, Gao AC.
Upregulation of glucose metabolism by NF-kappaB2/p52 med-
iates enzalutamide resistance in castration-resistant prostate cancer
cells. Endocr Relat Cancer. 2014;21:435–42.
2. Shafi AA, Putluri V, Arnold JM, Tsouko E, Maity S, Roberts JM,
et al. Differential regulation of metabolic pathways by androgen
receptor (AR) and its constitutively active splice variant, AR-V7,
in prostate cancer cells. Oncotarget. 2015;6:31997–2012.
3. Choi SY, Xue H, Wu R, Fazli L, Lin D, Collins CC, et al. The
MCT4 gene: a novel, potential target for therapy of advanced
prostate cancer. Clin Cancer Res. 2016;22:2721–33.
4. Altenberg B, Greulich KO. Genes of glycolysis are ubiquitously
overexpressed in 24 cancer classes. Genomics. 2004;84:1014–20.
5. Ranasinghe WK, Xiao L, Kovac S, Chang M, Michiels C, Bolton
D, et al. The role of hypoxia-inducible factor 1alpha in deter-
mining the properties of castrate-resistant prostate cancers. PLoS
ONE. 2013;8:e54251.
6. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear
PKM2 regulates beta-catenin transactivation upon EGFR activa-
tion. Nature. 2011;480:118–22.
7. Wang HJ, Hsieh YJ, Cheng WC, Lin CP, Lin YS, Yang SF, et al.
JMJD5 regulates PKM2 nuclear translocation and reprograms
HIF-1alpha-mediated glucose metabolism. Proc Natl Acad Sci
USA. 2014;111:279–84.
8. Wong N, Yan J, Ojo D, De Melo J, Cutz JC, Tang D. Changes in
PKM2 associate with prostate cancer progression. Cancer Invest.
2014;32:330–8.
9. Wang LY, Guo W, Kim K, Pochampalli M, Hung CL, Izumiya Y,
et al. Histone demethylases in prostate cancer. In: Kumar R,
editor. Nuclear signaling pathways and targeting transcription in
cancer. New York, NY: Springer, 2013.
10. Shin S, Janknecht R. Diversity within the JMJD2 histone deme-
thylase family. Biochem Biophys Res Commun. 2007;353:973–7.
11. Wissmann M, Yin N, Muller JM, Greschik H, Fodor BD, Jenu-
wein T, et al. Cooperative demethylation by JMJD2C and LSD1
promotes androgen receptor-dependent gene expression. Nat Cell
Biol. 2007;9:347–53.
12. Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vor-
reuther R, et al. Androgen receptor coactivators lysine-specific
histone demethylase 1 and four and a half LIM domain protein 2
predict risk of prostate cancer recurrence. Cancer Res.
2006;66:11341–7.
13. Cloos PA, Christensen J, Agger K, Maiolica A, Rappsilber J,
Antal T, et al. The putative oncogene GASC1 demethylates tri-
and dimethylated lysine 9 on histone H3. Nature.
2006;442:307–11.
14. Chu CH, Wang LY, Hsu KC, Chen CC, Cheng HH, Wang SM,
et al. KDM4B as a target for prostate cancer: structural analysis
and selective inhibition by a novel inhibitor. J Med Chem.
2014;57:5975–85.
15. Duan L, Rai G, Roggero C, Zhang QJ, Wei Q, Ma SH, et al.
KDM4/JMJD2 histone demethylase inhibitors block prostate
tumor growth by suppressing the expression of AR and BMYB-
regulated genes. Chem Biol. 2015;22:1185–96.
16. Oh S, Janknecht R. Histone demethylase JMJD5 is essential for
embryonic development. Biochem Biophys Res Commun.
2012;420:61–65.
17. Hsia DA, Tepper CG, Pochampalli MR, Hsia EY, Izumiya C,
Huerta SB, et al. KDM8, a H3K36me2 histone demethylase that
acts in the cyclin A1 coding region to regulate cancer cell pro-
liferation. Proc Natl Acad Sci USA. 2010;107:9671–6.
18. Zhu H, Hu S, Baker J. JMJD5 regulates cell cycle and plur-
ipotency in human embryonic stem cells. Stem Cells.
2014;32:2098–110.
19. Zhao Z, Sun C, Li F, Han J, Li X, Song Z. Overexpression of
histone demethylase JMJD5 promotes metastasis and indicates a
poor prognosis in breast cancer. Int J Clin Exp Pathol.
2015;8:10325–34.
20. Zhang R, Huang Q, Li Y, Song Y, Li Y. JMJD5 is a potential
oncogene for colon carcinogenesis. Int J Clin Exp Pathol.
2015;8:6482–9.
21. Ishimura A, Minehata K, Terashima M, Kondoh G, Hara T,
Suzuki T. Jmjd5, an H3K36me2 histone demethylase, modulates
embryonic cell proliferation through the regulation of Cdkn1a
expression. Development. 2012;139:749–59.
22. Huang X, Zhang S, Qi H, Wang Z, Chen HW, Shao J, et al.
JMJD5 interacts with p53 and negatively regulates p53 function in
control of cell cycle and proliferation. Biochim Biophys Acta.
2015;1853:2286–95.
23. Marcon E, Ni Z, Pu S, Turinsky AL, Trimble SS, Olsen JB, et al.
Human-chromatin-related protein interactions identify a deme-
thylase complex required for chromosome segregation. Cell Rep.
2014;8:297–310.
24. Amendola PG, Zaghet N, Ramalho JJ, Vilstrup Johansen J,
Boxem M, Salcini AE. JMJD-5/KDM8 regulates H3K36me2 and
is required for late steps of homologous recombination and gen-
ome integrity. PLoS Genet. 2017;13:e1006632.
25. Wu J, He Z, Yang XM, Li KL, Wang DL, Sun FL. RCCD1
depletion attenuates TGF-beta-induced EMT and cell migration
by stabilizing cytoskeletal microtubules in NSCLC cells. Cancer
Lett. 2017;400:18–29.
26. Youn MY, Yokoyama A, Fujiyama-Nakamura S, Ohtake F,
Minehata K, Yasuda H, et al. JMJD5, a Jumonji C (JmjC) domain-
containing protein, negatively regulates osteoclastogenesis by
facilitating NFATc1 protein degradation. J Biol Chem.
2012;287:12994–3004.
30 H-J Wang et al.
27. Liu H, Wang C, Lee S, Deng Y, Wither M, Oh S, et al. Clipping
of arginine-methylated histone tails by JMJD5 and JMJD7. Proc
Natl Acad Sci USA. 2017;114:E7717–E7726.
28. Shen J, Xiang X, Chen L, Wang H, Wu L, Sun Y, et al. JMJD5
cleaves monomethylated histone H3 N-tail under DNA damaging
stress. EMBO Rep. 2017;18:2131–43.
29. Ishimura A, Terashima M, Tange S, Suzuki T. Jmjd5 functions as
a regulator of p53 signaling during mouse embryogenesis. Cell
Tissue Res. 2016;363:723–33.
30. Wu BH, Chen H, Cai CM, Fang JZ, Wu CC, Huang LY, et al.
Epigenetic silencing of JMJD5 promotes the proliferation of
hepatocellular carcinoma cells by down-regulating the transcrip-
tion of CDKN1A 686. Oncotarget. 2016;7:6847–63.
31. He Z, Wu J, Su X, Zhang Y, Pan L, Wei H, et al. JMJD5 (Jumonji
Domain-containing 5) associates with spindle microtubules and is
required for proper mitosis. J Biol Chem. 2016;291:4684–97.
32. Huang X, Zhang L, Qi H, Shao J, Shen J. Identification and
functional implication of nuclear localization signals in the N-
terminal domain of JMJD5. Biochimie. 2013;95:2114–22.
33. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos
M, et al. Identification and validation of novel androgen-regulated
genes in prostate cancer. Endocrinology. 2004;145:3913–24.
34. DePrimo SE, Diehn M, Nelson JB, Reiter RE, Matese J, Fero M,
et al. Transcriptional programs activated by exposure of human
prostate cancer cells to androgen. Genome Biol. 2002;3:
RESEARCH0032.
35. Duan Z, Zou JX, Yang P, Wang Y, Borowsky AD, Gao AC, et al.
Developmental and androgenic regulation of chromatin regulators
EZH2 and ANCCA/ATAD2 in the prostate Via MLL histone
methylase complex. Prostate. 2013;73:455–66.
36. Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW,
et al. Intracrine Androgens and AKR1C3 Activation Confer
Resistance to Enzalutamide in Prostate Cancer. Cancer Res.
2015;75:1413–22.
37. Ku SY, Rosario S, Wang Y, Mu P, Seshadri M, Goodrich ZW,
et al. Rb1 and Trp53 cooperate to suppress prostate cancer lineage
plasticity, metastasis, and antiandrogen resistance. Science.
2017;355:78–83.
38. Luo W, Semenza GL. Emerging roles of PKM2 in cell metabo-
lism and cancer progression. Trends Endocrinol Metab.
2012;23:560–6.
39. Chaneton B, Hillmann P, Zheng L, Martin AC, Maddocks OD,
Chokkathukalam A, et al. Serine is a natural ligand and allosteric
activator of pyruvate kinase M2. Nature. 2012;491:458–62.
40. Keller KE, Tan IS, Lee YS. SAICAR stimulates pyruvate kinase
isoform M2 and promotes cancer cell survival in glucose-limited
conditions. Science. 2012;338:1069–72.
41. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S,
Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to
promote the Warburg effect and tumor growth. Sci Signal. 2009;2:
ra73.
42. Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, et al.
Immunoaffinity profiling of tyrosine phosphorylation in cancer
cells. Nat Biotechnol. 2005;23:94–101.
43. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, et al. Acetylation
targets the M2 isoform of pyruvate kinase for degradation through
chaperone-mediated autophagy and promotes tumor growth. Mol
Cell. 2011;42:719–30.
44. Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK,
Shen M, et al. Inhibition of pyruvate kinase M2 by reactive
oxygen species contributes to cellular antioxidant responses.
Science. 2011;334:1278–83.
45. Luo W, Hu H, Chang R, Zhong J, Knabel M, O’Meally R, et al.
Pyruvate kinase M2 is a PHD3-stimulated coactivator for
hypoxia-inducible factor 1. Cell. 2011;145:732–44.
46. Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2
regulates gene transcription by acting as a protein kinase. Mol
Cell. 2012;45:598–609.
47. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, et al. ERK1/2-
dependent phosphorylation and nuclear translocation of PKM2
promotes the Warburg effect. Nat Cell Biol. 2012;14:1295–304.
48. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-
Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is
involved in progression of prostate cancer. Nature. 2002;419:624–9.
49. Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer.
Protein Cell. 2013;4:331–41.
50. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA,
et al. Repression of E-cadherin by the polycomb group protein
EZH2 in cancer. Oncogene. 2008;27:7274–84.
51. Shin YJ, Kim JH. The role of EZH2 in the regulation of the
activity of matrix metalloproteinases in prostate cancer cells. PLoS
ONE. 2012;7:e30393.
52. Zhang Q, Padi SK, Tindall DJ, Guo B. Polycomb protein
EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
Cell Death Dis. 2014;5:e1486.
53. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald
TY, et al. Molecular characterization of neuroendocrine prostate
cancer and identification of new drug targets. Cancer Discov.
2011;1:487–95.
54. Chng KR, Chang CW, Tan SK, Yang C, Hong SZ, Sng NY, et al. A
transcriptional repressor co-regulatory network governing androgen
response in prostate cancers. EMBO J. 2012;31:2810–23.
55. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, et al. EZH2
oncogenic activity in castration-resistant prostate cancer cells is
Polycomb-independent. Science. 2012;338:1465–9.
56. Alumkal JJ, Herman JG. Distinct epigenetic mechanisms distin-
guish TMPRSS2-ERG fusion-positive and -negative prostate
cancers. Cancer Discov. 2012;2:979–81.
57. Clermont PL, Lin D, Crea F, Wu R, Xue H, Wang Y, et al.
Polycomb-mediated silencing in neuroendocrine prostate cancer.
Clin Epigenetics. 2015;7:40.
58. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP,
et al. Niclosamide inhibits androgen receptor variants expression
and overcomes enzalutamide resistance in castration-resistant
prostate cancer. Clin Cancer Res. 2014;20:3198–210.
59. Li H, Hassona MD, Lack NA, Axerio-Cilies P, Leblanc E,
Tavassoli P, et al. Characterization of a new class of androgen
receptor antagonists with potential therapeutic application in
advanced prostate cancer. Mol Cancer Ther. 2013;12:2425–35.
60. Ma AH, Xia L, Desai SJ, Boucher DL, Guan Y, Shih HM, et al.
Male germ cell-associated kinase, a male-specific kinase regulated
by androgen, is a coactivator of androgen receptor in prostate
cancer cells. Cancer Res. 2006;66:8439–47.
61. Zou JX, Guo L, Revenko AS, Tepper CG, Gemo AT, Kung HJ,
et al. Androgen-induced coactivator ANCCA mediates specific
androgen receptor signaling in prostate cancer. Cancer Res.
2009;69:3339–46.
62. Yang P, Guo L, Duan ZJ, Tepper CG, Xue L, Chen X, et al. Histone
methyltransferase NSD2/MMSET mediates constitutive NF-kappaB
signaling for cancer cell proliferation, survival, and tumor growth
via a feed-forward loop. Mol Cell Biol. 2012;32:3121–31.
63. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R,
Ghosh D, et al. ONCOMINE: a cancer microarray database and
integrated data-mining platform. Neoplasia. 2004;6:1–6.
KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC 31
Affiliations
Hung-Jung Wang1,2 ● Mamata Pochampalli3 ● Ling-Yu Wang3 ● June X Zou3 ● Pei-Shan Li2 ● Sheng-Chieh Hsu1,4 ●
Bi-Juan Wang5 ● Shih-Han Huang5 ● Ping Yang6,7 ● Joy C. Yang6 ● Cheng-Ying Chu8 ● Chia-Ling Hsieh8 ●
Shian-Ying Sung8 ● Chien-Feng Li9 ● Clifford G. Tepper 6 ● David K. Ann8,10 ● Allen C. Gao1,6 ●
Christopher P. Evans6,11 ● Yoshihiro Izumiya11 ● Chi-Pin Chuu5 ● Wen-Ching Wang12 ● Hong-Wu Chen3,11 ●
Hsing-Jien Kung2,3,4,8
1 Institute of Biotechnology and Pharmaceutical Research, National
Health Research Institutes, 35053 Miaoli County, Taiwan
2 Institute of Molecular and Genomic Medicine, National Health
Research Institutes, 35053 Miaoli County, Taiwan
3 Department of Biochemistry and Molecular Medicine, School of
Medicine, University of California, Davis, CA 95817, USA
4 Institute of Biotechnology, National Tsing-Hua University, 30035
Hsinchu, Taiwan
5 Institute of Cellular and System Medicine, National Health
Research Institutes, 35053 Miaoli County, Taiwan
6 Department of Urology, School of Medicine, University of
California, Davis, CA 95817, USA
7 State Key Laboratory of Oncology in South China, Collaborative
Innovation Center for Cancer Medicine, Sun Yat-sen University
Cancer Center, Guangzhou, China
8 Ph.D. Program for Translational Medicine, College of Medical
Science and Technology, Taipei Medical University, Taipei City,
Taiwan
9 National Institute of Cancer Research, National Health Research
Institutes, 35053 Miaoli County, Taiwan
10 Department of Molecular Pharmacology, Beckman Research
Institute, City of Hope, Duarte, CA, USA
11 Comprehensive Cancer Center, School of Medicine, University of
California, Davis, Sacramento, CA, USA
12 Institute of Molecular and Cellular Biology, National Tsing-Hua
University, Hsinchu, Taiwan
32 H-J Wang et al.
